Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to $172000.0.

  • Angiodynamics' Asset Writedowns and Impairment rose 4576.27% to $172000.0 in Q4 2025 from the same period last year, while for Nov 2025 it was $591000.0, marking a year-over-year increase of 10039.78%. This contributed to the annual value of $699000.0 for FY2025, which is 9016.6% down from last year.
  • Per Angiodynamics' latest filing, its Asset Writedowns and Impairment stood at $172000.0 for Q4 2025, which was up 4576.27% from $108000.0 recorded in Q3 2025.
  • Angiodynamics' Asset Writedowns and Impairment's 5-year high stood at $14.0 million during Q2 2021, with a 5-year trough of -$152.4 million in Q2 2024.
  • In the last 5 years, Angiodynamics' Asset Writedowns and Impairment had a median value of $146000.0 in 2022 and averaged -$6.9 million.
  • Over the last 5 years, Angiodynamics' Asset Writedowns and Impairment had its largest YoY gain of 192380.95% in 2024, and its largest YoY loss of 11296518.52% in 2024.
  • Over the past 5 years, Angiodynamics' Asset Writedowns and Impairment (Quarter) stood at $141000.0 in 2021, then soared by 116.31% to $305000.0 in 2022, then soared by 184.92% to $869000.0 in 2023, then plummeted by 86.42% to $118000.0 in 2024, then skyrocketed by 45.76% to $172000.0 in 2025.
  • Its Asset Writedowns and Impairment was $172000.0 in Q4 2025, compared to $108000.0 in Q3 2025 and $169000.0 in Q2 2025.